Isolated Lactobacillus strains are useful in preventing or delaying the development of Type 1 Diabetes (T1D). A probiotic composition comprising the Lactobacillus strains and use of the composition in T1D prevention are provided.

The present invention relates to a method of forming dihydroferulic acid comprising providing ferulic acid and incubating the ferulic acid with a bacterial preparation of Lactobacillus johnsonii CNCM 1-1225 or a bacterial preparation of natural derivatives of Lactobacillus johnsonii CNCM 1-1225. An aspect of the invention is a composition comprising dihydroferulic acid and a bacterial preparation of Lactobacillus johnsonii CNCM 1-1225 or its natural derivatives. A further aspect of the invention is a composition comprising ferulic acid and a bacterial preparation of Lactobacillus johnsonii CNCM 1-1225 or its natural derivatives for use in the treatment or prevention of metabolic disease. Further aspects of the invention are the use of a bacterial preparation of Lactobacillus johnsonii CNCM 1-1225 or its natural derivatives; and a kit for preparing a food product.

A sweetener composition comprising xylose, a sugar alcohol and brown seaweed extract in solid form, preferably powdered or crystalline form. The sugar alcohol is preferably an erythritol and the brown seaweed extract is preferably obtained from Laminaria japonica. The sweetener composition can further comprise one or a combination of additional vitamins, minerals, probiotic cultures, and other plant-based extracts.

A composition containing the probiotic strain Lactobacillus johnsonii CNCM 1-1225 in combination with a polyphenol for use in the treatment or prevention of a cognitive and/or neurodegenerative disorder, in particular Alzheimer's disease. The polyphenol can be one or more of rosmarinic acid, chicoric acid, or caftaric acid, and can be provided in the form of a plant extract.

Inoculation of ATM-deficient mice with probiotic microorganisms, such as L. johnsonii, changed immune parameters, decreased a marker of DNA damage and increased the lifespan of the mice. Compositions and methods described herein are useful for the treatment and prevention of Ataxia telangiectasia and other cancer-prone disease, such as p53 deficiency-associated cancers. Compositions and methods of the present invention are also useful for treating and preventing radiation-induced toxicity to normal tissue in a subject being exposed to radiation, Compositions and methods of the invention can increase lifespans in a simple, non-invasive manner.

A sweetener composition comprising xylose, a sugar alcohol and brown seaweed extract in solid form, preferably powdered or crystalline form. The sugar alcohol is preferably an erythritol and the brown seaweed extract is preferably obtained from Laminaria japonica. The sweetener composition can further comprise one or a combination of additional vitamins, minerals, probiotic cultures, and other plant-based extracts.

The present invention relates to a composition comprising one or more fructanases and one or more Lactobacillus strains to provide relief from or prevent fructan and/or fructose induced abdominal discomfort; digest fructan and/or fructose or improve digestion of fructan and/or fructose; and/or provide digestive comfort after digestion of fructan and/or fructose on consumption of products containing fructan and/or fructose to a subject. The present invention also relates a Lactobacillus strain or a fructanse for providing relief from fructan and/or fructose induced abdominal discomfort to a subject, wherein the Lactobacillus strain in presence of one or more fructanases results in at least 20-50% reduction of gas pressure development, when tested against the fecal fermentation of the fiber alone across different donors.

The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children.

The present invention relates to a composition comprising at least one human milk oligosaccharide and/or a precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants or young children born by C-section.